Novel thrombin inhibitors, bacithrocins A, B and C, have been isolated from the culture broth of Bacillus laterosporus Laubach NR2988. The structures of these inhibitors have been determined to be 7V-acyl-L-phenylalanyl-DL-arginal by the 2D-NMR experiments on their oxidation products and by amino acid analysis. Bacithrocin A inhibits thrombin, factor Xaand trypsin with IC5Osof 48, 13 and 0.65^m, respectively, which are similar to those of bacithrocins B and C.
Bacithrocins prolong the clotting time induced by thrombin and factor Xa.
Thrombin, one of the serine proteases, plays a key role in blood coagulation. It converts fibrinogen into fibrin and activates the co factors V and VIII, and also induces platelet aggregation itself. Therefore, a specific inhibitor of thrombin can be an effective anticoagulant agent for the treatment of diseases caused by an aberration of this enzymeactivity. In our screening program for thrombin inhibitors, we isolated novel thrombin inhibitors, bacithrocins A (1), B (2) and C (3) from the culture broth of a strain, NR 2988 ( Fig. 1) . The strain was isolated from a soil sample collected at Iruma, Saitama Prefecture, Japan and was identified as Bacillus laterosporus Laubach based on its morphological and physiological properties1}. Another component, bacithrocin D (4), which was characterized and identified as thiolstatin D2'3) was also isolated with these inhibitors. In the present paper, we describe the fermentation, isolation, structural elucidation and biological activity of these four inhibitors.
Results

Fermentation
The stock culture ofB. laterosporus NR 2988, stored at -80°C, was thawed, and 200fA of the culture was inoculated into a 500-ml Erlenmeyer flask containing 100ml of a seed mediumconsisting of glucose 2.0%, dextrin 2.0%, S-III meat (Ajinomoto Co. Inc.) 1.5%, Pharmamedia (Traders  Protein) 1.5%, K2HPO4 0.06% and KH2PO4 0.025%. The flask was agitated at 190rpm on a rotary shaker at 27°C for 1 day. Then, 30ml of the culture was transferred to a 50-liter jar fermentor containing 30 liters of production medium having the same composition as the seed medium. The fermentation was carried out at 27°C for 3 days with aeration of 30 liters/minute and with agitation of 300 rpm. Isolation Isolation of bacithrocins was carried out by Bacithrocins A (836mg), B (400mg), C (588mg) and D (500mg) were isolated as colorless powders from the broth filtrate (60 liters) by «-butanol extraction followed by chromatography with SP-Toyopearl and Sephadex LH-20. Details of the isolation procedure are described in the experimental section.
Physico-chemical Properties The physico-chemical properties of 1, 2, 3 and 4 are summarized in Table 1 . The molecular formulae of 1, 2, 3 and 4 were determined to be C20H31N5O3, C19H29N5O3, C18H27N5O3 and C17H25N5O3
respectively, from HRFAB-MSdata. The IR spectra (Fig. 3 ) of bacithrocins suggested that these inhibitors are peptidic compoundsand structurally related to thiolstatin D, iV-acetylphenylalanylarginal2'3). Acid hydrolysis of the bacithrocins in 6 n HC1 at 120°C for 15 hours followed by TLC and chiral HPLCanalysis indicated that the compounds contained L-phenylalanine. GC-MSanalysis of the hydrolysates of 1, 2, 3 and 4 indicated the presence ofisovaleric acid, isobutyric acid, propionic acid and acetic acid, respectively.
Since AHand 13C NMRspectra of 1 were very complicated due to its tautomerism, analysis of the NMRspectra was quite difficult. However, a weak signal at Sn 9.27 suggested the presence of an aldehyde functionality, and that was further supported by a blue coloration in the blue tetrazolium reaction. The presence of a guanidino group was also indicated by an orange coloration in the Sakaguchi reaction. Taking the molecular fonnula, C20H31N5O3, into consideration, it is reasonable to assign the structural unit other than the phenylalanine residue (C9H9NO)and the isovaleric acid residue (C5H9O)to an arginal unit (C6H13N4O) containing the aldehyde and guanidino groups. Since an aldehyde proton signal wasobserved at SH 9.27 in the XH NMRspectrum of 1 and its intensity was weak, the aldehyde functionality was suggested to be involved in the tautomerism similar to the case with Ieupeptin4'5).
In order to avoid this tautomerism, the aldehyde was oxidized to a carboxylic acid. Bacithrocin A was treated with platinum black under O2 at pH 7.4 to give the oxidation products, la (C20H31N5O4) and lb (C2oH31N504). The TLC and chiral HPLC analysis of the hydrolysate of la and lb indicated that la and lb possessed l-and D-arginine residues, respectively, in addition to L-phenylalanine. This result suggested that the C-terminal end of 1 was a mixture of l-and
The structural elucidation of lb was accomplished by the NMRexperiments. The 1H and 13C NMR spectral data of lb are summarized in Table 2 . The *H signals were assigned by homo decoupling and COSYexperiments. The sequence of isovaleric acid and amino acid residues was determined based on the following 13C-1H long range couplings obtained by an HMBCexperiment on lb: between 2-H (SH 3.98) and C-l' (Sc 169.9) and between 2-NH (<5H 7.50) and C-l' , and also between 2'-NH (SH 8.16) and C-l" (5C 171.4), as shown in Fig. 4 . Thus, the structure of lb was determined to be iV-isovaleryl-L-phenylalanyl-
In a similar manner, the structure of la was determined to be JV-isovaleryl-L-phenylalanyl-L-arginine. The structure of la was also confirmed by comparing its physico-chemical data with those of the corresponding synthesized sample (see experimental section). Therefore, the structure of 1 was deduced to be AMsovaleryl-L-phenylalanyl-DL-arginal ( Fig. 1 ).
Structural Elucidation of 2, 3 and 4 The structures of 2, 3 and 4 were also determined based on the structural elucidation of their oxidation products. The oxidation of2, 3 and 4 gave 2a and 2b, 3a and 3b and 4a and 4b, respectively (Fig. 5) . The TLCand chiral HPLCanalysis of the hydrolysate of these oxidation products indicated that the compounds possessed l-or D-arginine and L-phenylalanine, whereas 2, 3 and 4 possessed only L-phenylalanine. This result indicated that the C-terminal ends of 2, 3 and 4 were also l-and D-arginal. Since their XHNMR spectral data were quite similar to those of la and lb except for the signals assigned to the carboxylic acid residues and hydrolysis of 2, 3 and 4 gave isobutyric acid, propionic acid and acetic acid, respectively, the structures of 2a, 2b, 3a, 3b, 4a and 4b were suggested as shown in Fig. 5 . To confirm the structures, we synthesized AMsobutyryl-L-phenylalanyl-L-arginine, 7V-propionyl-L-phenylalanyl-L-arginine and 7V-acetyl-L-phenylalanyl-L-arginine and compared their physico-chemical data with those of the oxidation products 2a, 3a and 4a. The physico-chemical properties of 2a, 3a and 4a were identical with those of the synthesized authentic samples. Therefore, the structures of 2, 3 and 4 were deduced to be AMsobutyryl-L-phenylalanyl-
7V-propionyl-L-phenylalanyl-DL-arginal and iV-acetyl-L-phenylalanyl-DL-arginal, respectively (Fig.1 ).
The structures of 1, 2, 3 and 4 were further confirmed by the analysis of their FAB-MSdata. Common fragment peaks attributable to the arsinal and ohenvlalanine residues were observed at mlz 185. 142 and 120 in the FAB-MS of 1, 2, 3 and 4 ( Fig. 6 ).
Successive fragmentations caused by the successive loss of amino acids from the C-terminal end revealed the order of the linkages and also the alteration of carboxylic acids (Fig. 6) . Therefore, the structures of bacithrocins were unambiguously established, as shown in Fig. 1 , and bacithrocin D was revealed to be identical to thiolstatin D2'3). Bacithrocins and leupeptin are characterized by the tautomerism caused by having an arginal moiety in the molecule. Thiolstatin D was reported as a single isomer, but it is likely that thiolstatin D exists in solution as a mixture of tautomers as do the bacithrocins. Compound Biological Activity The inhibitory activities of the bacithrocins against three serine proteases, thrombin, factor Xa and trypsin, and a thiol protease, papain, are shownin Table 3 . The effects of bacithrocins on prolonging clotting time are also characterized by the IC50 value (>m) indicating the concentration of the compound leading to a clotting time twice that of the control (Table 3) . It is well known that the factor Xa-induced plasma clotting involves enzymatic reactions of both thrombin and factor Xa. The result that bacithrocins show a more potent prolongation effect on the factor Xa-induced clotting time than on the thrombin-induced clotting time may be attributable to the stronger inhibitory action against factor Xa than against thrombin. 
Experimental General Procedures
UVspectra were recorded on a KONTRON Uvikon 860 UVspectrometer, and IR spectra on a Hitachi 270-30 or Perkin Elmer 1600 IR spectrometer. FAB-MS, HRFAB-MSand GC-MSwere measured on JEOL JMS-DX303, JMS-SX102 and JMS-AX505 mass spectrometers, respectively. *H and 13C NMR were recorded on a JMN-GSX-400NMRspectrometer at 400 and 100 MHz, respectively, using TMSas an internal standard. Optical rotations were measured on a JASCODIP-140 digital polarimeter.
Isolation of Bacithrocins
In the following procedure, the fractions were monitored by the thrombin inhibitory activities measured. The broth filtrate (60 liters) was adjusted to pH 8.0 with 6n NaOHand extracted with w-butanol. The organic layer was concentrated under reduced pressure. The residue was dissolved in H2O(5 liters) and VOL.47 NO. 9 THE JOURNAL OF ANTIBIOTICS 965 then applied to a SP-Toyopearl (Na+ form, course grade) column (7 x 130 cm) and the column was washed with H2O (20 liters) and with 50 mMNaCl solution (25 liters), and then eluted with 100 him NaCl solutions (50 liters). The active fractions (100 mMNaCl fractions) were collected, adjusted to pH 7.0, concentrated and lyophilized. The residual powder was suspended in methanol and stirred for 30 minutes. Insoluble substances were removed by filtration, and the filtrate was concentrated under reduced pressure to give the crude mixture of bacithrocins. Then, these inhibitors were separated by preparative HPLCover a C8 reversed-phase column of YMCpack SH-263-10 (30mmi.d. x 250mm) using methanol -50 mMphosphate buffer, pH 7.6 (45 : 55). Each fraction was evaporated to remove the methanol and extracted with w-butanol at pH 8.0. The w-butanol extracts were concentrated to dryness. The crude bacithrocins A, B, C and D were separately dissolved in 5 ml of methanol and then applied to a Sephadex LH-20 column (2 x 140cm) eluted with methanol -acetic acid (99.9 : 0. 1). The active fractions were collected, concentrated under reduced pressure and lyophilized to give 1 (836mg), 2 (400mg), 3 (588mg) and 4 (500mg) as white powders.
Acid Hydrolysis of Bacithrocins and Their Derivatives
A solution of the sample (3mg) in 6n HC1 (lml) was stirred at 120°C for 15 hours. The reaction mixture was evaporated to dryness. The residue was dissolved in H2O (4ml) and CHC13(4ml). The aqueous layer was concentrated and applied to the TLCand chiral HPLCanalysis for the determination of amino acid composition and its chirality. The organic layer was concentrated and applied to the GC-MS analysis for the determination of carboxylic acid residue. The following conditions were used. TLCanalysis: Table 2 .
Oxidation of 2
Bacithrocin B (lOO mg) was treated with Pt-black under the same conditions for 1. After the removal of Pt-black, the reaction mixture was concentrated under reduced pressure. The concentrate was purified by preparative HPLCover a C8 reversed-phase silica gel column with MeOH-H2O (20 : 80) at a flow rate of 30ml/minute to give 12. Oxidation of 3
Bacithrocin C (lOO mg) was treated with Pt-black under the same conditions for 1. After the removal of Pt-black, the reaction mixture was concentrated under reduced pressure. The concentrate was purified by preparative HPLCover a C8 reversed-phase silica gel column with MeOH-H2O (20 : 80) at a flow rate of 30 ml/minute to give 14.4mg of 3a (retention time, 17.6 minutes) and 21.4mg of 3b (retention time, 22.2 minutes) as powders. 3a amino acid composition: L-phenylalanine and L-arginine; HRFAB-MSm/z calcd for C18H28N5O4: 378.2141, found 378.2147 (M+H)+; IR vmax (KBr): 3500-3000, 1650, 1400, 700cm"1; *H NMR (400MHz, DMSO-d6): 0.88 (3H, t, /=8.0Hz), 1 Bacithrocin D (lOO mg) was treated with Pt-black under the same conditions for 1. After the removal of Pt-black, the reaction mixture was concentrated under reduced pressure. The concentrate was purified by preparative HPLC over a C8 reversed-phase silica gel column with MeOH-H2O (15 : 85) at a flow rate of 30ml/minute to give 13.5mg of 4a (retention time, 14.0minutes) and 20. Preparation of la, AMsovaleryl-L-phenylalanyl-L-arginine L-phenylalanyl-L-arginine -2TFA l/2H2O (20mg) was dissolved in pyridine (l ml). To this solution was added 20fi\ of isovaleric anhydride with stirring at roomtemperature. The solution was stirred for 5 hours, and the solvent was evaporated under reduced pressure. The residue was dissolved in 2ml of 100 mMphosphate buffer (pH 8.0) and purified first by preparative HPLCover a C18 reversed-phase silica gel column (YMC R-ODS-10, 4.6mm i.d. x 250mm, YMCCo., Ltd.) with 50% aqueous MeOHat a flow rate of3.0 ml/minute (retention time, 4. 1 minutes) and second by preparative HPLCover a C8 reversed-phase silica gel column (Capcell pak C8 SG, 10mmi.d. x 250mm, Shiseido) with 35% aqueous MeOHat a flow rate of 5.0 ml/minute to give 3.5 mg ofAMsovaleryl-L-phenylalanyl-L-arginine (retention time, 1 5.9 minutes). Preparation of 4a, iV-acetyl-L-phenylalanyl-L-argmine L-Phenylalanyl-L-arginine à" 2TFA à" 1/2H2O (20 mg) and acetic anhydride (10 /il) were stirred in pyridine (1 ml) at room temperature for 5 hours. The reaction mixture was purified first by preparative HPLCover a C18 reversed-phase silica gel column with 40% aqueous MeOHat a flow rate of 2.0 ml/minute (retention time, 3.3 minutes) and second by preparative HPLCover a C8 reversed-phase silica gel column with 20% aqueous MeOHat a flow rate of 5.0 ml/minute to give 2.9 mg of N-propionyl-L-phenylalanyl-L-arginine (retention time, 10.2 minutes).
Enzyme Assays Using Fluorogenic Substrates6) The mixture of 195/xl of an enzyme solution (final concentration ; 0.08u/ml thrombin, 0.015u/ml factor Xa, 0.03u/ml trypsin and 0.076u/ml papain) and an inhibitor solution (50^1) was incubated at 37°C. After 1 minute, a substrate solution (5 fi\) in DMSO(final concentration; 20 /xm Boc-Val-Pro-Argmethylcoumarylamide (MCA) for thrombin, 120 /xm Boc-Ile-Glu-Gly-Arg-MCA for factor Xa and 120^M Bz-Arg-MCAfor trypsin and papain) was added. Fluorescence of 7-amino-4-methylcoumarin produced was monitored in 30 seconds intervals for up to 180 seconds using a spectrophotometric centrifugal analyzer (Cobas Bio, Roche Diagnostica Inc.) at 380 nm extention and 460 nm emission wavelength.
Clotting Assays
The two clotting assays (thrombin-induced fibrinogen clotting time, factor Xa-induced clotting time) were performed using a fibrometer (Cobas Fibro, Roche Diagnostica Inc.) as described by H. P. Wessel et aL7). Briefly, the time required to form fibrin fiber was measured aTter 2.5 NIHunits of bovine thrombin was added to 1 ng/ml of fibrinogen for thrombin-induced clotting time. For factor Xa-induced clotting time, factor Xa (0.2mu/ml) was incubated for 2 minutes at 37°C in the presence of lOmMCaCl2. Clotting time was determined after the addition of mixture of factor Xa-deficient plasma and rabbit brain cephalin (Sigma) .
